Signature Estate & Investment Advisors LLC Decreases Stock Position in Thermo Fisher Scientific Inc. $TMO

Key Points

• Signature Estate & Investment Advisors LLC significantly reduced its stake in Thermo Fisher Scientific Inc. by 74% in the second quarter, owning 22,090 shares valued at approximately $8.96 million.
• Multiple institutional investors have increased their positions in Thermo Fisher, with Brighton Jones LLC boosting its shares by 28.9% in the fourth quarter.
• Analysts have varying ratings on the stock, with Weiss Ratings reissuing a "hold" rating and Raymond James Financial setting an upward target price of $535.00, reflecting a consensus of "Moderate Buy".

Signature Estate & Investment Advisors LLC cut its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 74.0% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 22,090 shares of the medical research company's stock after selling 62,852 shares during the period. Signature Estate & Investment Advisors LLC's holdings in Thermo Fisher Scientific were worth $8,957,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in TMO. Brighton Jones LLC boosted its position in shares of Thermo Fisher Scientific by 28.9% in the 4th quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company's stock worth $2,293,000 after buying an additional 988 shares in the last quarter. Revolve Wealth Partners LLC raised its stake in Thermo Fisher Scientific by 4.2% in the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company's stock valued at $255,000 after purchasing an additional 20 shares during the last quarter. GAMMA Investing LLC raised its stake in Thermo Fisher Scientific by 22.0% in the 1st quarter. GAMMA Investing LLC now owns 4,862 shares of the medical research company's stock valued at $2,419,000 after purchasing an additional 877 shares during the last quarter. CWA Asset Management Group LLC raised its stake in Thermo Fisher Scientific by 4.3% in the 1st quarter. CWA Asset Management Group LLC now owns 1,435 shares of the medical research company's stock valued at $714,000 after purchasing an additional 59 shares during the last quarter. Finally, Blue Trust Inc. raised its stake in Thermo Fisher Scientific by 22.0% in the 1st quarter. Blue Trust Inc. now owns 1,249 shares of the medical research company's stock valued at $621,000 after purchasing an additional 225 shares during the last quarter. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

TMO has been the subject of several analyst reports. Weiss Ratings reissued a "hold (c)" rating on shares of Thermo Fisher Scientific in a research note on Tuesday, October 14th. Wall Street Zen downgraded shares of Thermo Fisher Scientific from a "buy" rating to a "hold" rating in a research note on Sunday, October 12th. Raymond James Financial reissued an "outperform" rating and issued a $535.00 target price (up previously from $525.00) on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. Wells Fargo & Company cut their price objective on shares of Thermo Fisher Scientific from $570.00 to $565.00 and set an "overweight" rating on the stock in a report on Thursday, July 24th. Finally, Barclays boosted their target price on shares of Thermo Fisher Scientific from $550.00 to $585.00 and gave the company an "overweight" rating in a report on Thursday, October 2nd. Fifteen investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $589.10.

Insider Buying and Selling

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 400 shares of the company's stock in a transaction that occurred on Friday, September 5th. The stock was sold at an average price of $500.50, for a total value of $200,200.00. Following the completion of the transaction, the chief executive officer owned 113,762 shares in the company, valued at $56,937,881. This represents a 0.35% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Gianluca Pettiti sold 400 shares of the company's stock in a transaction that occurred on Friday, July 25th. The stock was sold at an average price of $479.98, for a total value of $191,992.00. Following the completion of the transaction, the executive vice president owned 22,367 shares of the company's stock, valued at approximately $10,735,712.66. This represents a 1.76% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 30,066 shares of company stock valued at $14,182,963. 0.33% of the stock is currently owned by corporate insiders.

Thermo Fisher Scientific Stock Up 0.4%

TMO opened at $539.05 on Friday. The firm has a 50 day moving average price of $495.74 and a 200 day moving average price of $449.13. The company has a market cap of $203.55 billion, a PE ratio of 31.18, a price-to-earnings-growth ratio of 2.93 and a beta of 0.77. Thermo Fisher Scientific Inc. has a 1 year low of $385.46 and a 1 year high of $610.97. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.22 by $0.14. The firm had revenue of $10.86 billion during the quarter, compared to the consensus estimate of $10.68 billion. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The company's revenue was up 2.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $5.37 EPS. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Sell-side analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.